Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): Frequency and response to treatment

AIDS

Volumn 16, Issue 5, 2002, Pages 793-796

  Harzic, Martine ^a   Pellegrin, Isabelle ^b   Deveau, Christiane ^c   Chaix, Marie Laure ^e   Dubeaux, Béatrice ^a   Garrigue, Isabelle ^b   Ngo, Nicole ^e   Rouzioux, Christine ^e   Goujard, Cécile ^d   Hoen, Bruno ^f   Sereni, Daniel ^g   Delfraissy, Jean Francois ^d   Meyer, Laurence ^h  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b HÔPITAL PELLEGRIN   (France)

^c INSERM   (France)

^d BICÊTRE HOSPITAL   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f HÔPITAL SAINT JACQUES   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; FEMALE; FRANCE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; FRANCE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MALE; RITONAVIR; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 0037192583     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203290-00017     Document Type: Article

References (12)

1. Primary infection with zidovudine resistant human immuno-deficiency virus type 1
2. Prevalence and clinical course of persons seroconverting with AZT-resistant HIV-1 in Switzerland, Austria and United States between 1988 and 1994
3. HIV-1 drug resistance in newly infected individuals
4. Prevalence of drug resistance mutations in patients with primary HIV-1 infection
5. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
6. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection
7. Transmission of antiretroviral-drug-resistant HIV-1 variants
8. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial
9. Weak anti-HIV CD8+ T cell effector activity in HIV primary infection
10. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug
11. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users